251
Participants
Start Date
June 13, 2018
Primary Completion Date
July 22, 2019
Study Completion Date
August 21, 2019
AGN-241751
AGN-241751 administered orally as a single tablet
Placebo
Placebo administered orally as a single tablet
Eastside Comprehensive Medical Center, New York
Synexus US - Queens, Jamaica
Neurobehavioral Research, Inc, Cedarhurst
Finger Lakes Clinical Research, Rochester
Synexus US - Atlanta, Atlanta
Atlanta Center for Medical Research, Atlanta
Clinical Neuroscience Solutions, Inc - Memphis, TN, Memphis
Research Strategies of Memphis, LLC, Memphis
Neuro-Behavioral Clinical Research, Inc, North Canton
Pillar Clinical Research, Lincolnwood
Health Initiatives Research PLLC, Fayetteville
IPS Research, Oklahoma City
FutureSearch Trials of Dallas, LP, Dallas
Donald J. Garcia, Jr., MD, PA, Austin
Collaborative Neuroscience Network, Torrance
Synexus US - Cerritos, Cerritos
Wake Research - Pharmacology Research Institute, Encino
North County Clinical Research, Inc., Oceanside
Elite Clinical Trials, Inc., Wildomar
Wake Research - Pharmacology Research Institute, Newport Beach
Pacific Research Partners, LLC, Oakland
Northwest Clinical Research Center, Bellevue
Boston Clinical Trials, Boston
Hassman Research Institute, Berlin
Center for Emotional Fitness, Cherry Hill
Syndeio Biosciences, Inc
INDUSTRY